INCR
InterCure Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$5.42
+3.04%Year over year
Reported trailing growth
- Revenue
- +13.1%
- EBITDA
- +30.2%
- EBIT
- +59.5%
- EPS
- +24.6%
- Free cash flow
- +211.4%
- Operating cash flow
- +244.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.4%
- EBITDA
- +85.8%
- EBIT
- -49.0%
- Net income
- +47.3%
- EPS
- +55.6%
- Free cash flow
- -25.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025